Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Summary Checkpoint inhibitor (CPI) therapy has vastly improved long‐term outcomes in metastatic malignant melanoma (MMM). Therapy takes the form of monoclonal antibody infusions that target immune cell checkpoint proteins, such as cytotoxic T‐lymphocyte‐associated protein 4 (CTLA4) and programmed death 1/programmed death ligand 1 (PD1/PDL1).
A. Gault C. Dobeson S. Haney J. Graham A. Humphreys Purpose: Neoadjuvant chemotherapy can allow for breast conserving surgery to be undertaken and for assessment of tumour response to therapy, inferring prognostic implications. We reviewed outcomes for all patients receiving neoadjuvant chemotherapy, in terms of pathological complete response (pCR) rates, to see if these were comparable with published data [1].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.